Cargando…
Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA
OBJECTIVES: The aim was to evaluate retention rates for secukinumab in patients with active PsA or radiographic axial spondyloarthritis (r-axSpA) treated in routine UK clinical practice. METHODS: SERENA (CAIN457A3403) is an ongoing, non-interventional, international study of patients with moderate-t...
Autores principales: | Gaffney, Karl, Gullick, Nicola, MacKay, Kirsten, Patel, Yusuf, Sengupta, Raj, Sheeran, Tom, Hemmings, Louise, Pamies, Paula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472087/ https://www.ncbi.nlm.nih.gov/pubmed/37663578 http://dx.doi.org/10.1093/rap/rkad055 |
Ejemplares similares
-
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
por: Kiltz, Uta, et al.
Publicado: (2022) -
Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis
por: Jadon, Deepak R, et al.
Publicado: (2017) -
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
por: Kiltz, Uta, et al.
Publicado: (2020) -
Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
por: Aparicio, María, et al.
Publicado: (2021) -
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)